Aligos' fatty liver disease treatment meets main goal in mid-stage study
19/09/2024 13:03
Sept 19 (Reuters) - Aligos Therapeutics ALGS.O said on Thursday its experimental treatment for a serious type of fatty liver disease helped significantly reduce liver fat, meeting the main goal of a mid-stage study. (Reporting by Mariam Sunny in Bengaluru; Editing by Vijay Kishore) ((Mariam.ESunny@thomsonreuters.com;))
Recent news on Aligos Therapeutics
See all newsUS FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment (updated)
U.S. RESEARCH ROUNDUP-Ciena Corp, Docusign, Snowflake
Brief: Aligos Therapeutics Announces First Participant Dosed In The Phase 1 Study Of Its Potentially Best-In-Class Antisense Oligonucleotide Alg-170675 By Its Partner Amoytop In China
Aligos Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Aligos Therapeutics Q2 net loss narrows on licensing revenue